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structures. However, glycoconjugate samples are often 
very complex and heterogeneous and contain many diverse 
branched glycan structures. In this article we cover HTP 
sample preparation and derivatization methods, sample 
purification, robotization, optimized glycan profiling by 
UHPLC, MS and multiplexed CE, as well as hyphenated 
techniques and automated data analysis tools. Throughout, 
we summarize the advantages and challenges with each of 
these technologies. The issues considered include reliabil-
ity of the methods for glycan identification and quantita-
tion, sample throughput, labor intensity, and affordability 
for large sample numbers.
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Introduction
This review focuses on advances in analytical technolo-
gies for high-throughput (HTP) glycomics (i.e. the large-
scale study of glycoconjugate glycosylation patterns). Our 
emphasis will be on glycomics to support (1) realization of 
glycoprotein biopharmaceuticals and (2) development of 
glycan biomarkers of disease for clinical diagnostics.
Glycans play key roles in important biological processes 
such as protein folding, host-pathogen interaction and sig-
nal transduction [1]. They are present both in free form, or 
bound to proteins or lipids, and can modify the biological 
activities of the conjugate. The glycomics technologies 
covered in this review are mainly for analysis of protein 
glycosylation, the major types of which are N-linked gly-
cans attached at Asn-X-Ser/Thr motifs on the peptide back-
bone and O-linked glycans attached to Ser/Thr [2]. Protein 
glycosylation is a co-translational and post-translational 
Abstract This review covers advances in analytical tech-
nologies for high-throughput (HTP) glycomics. Our focus 
is on structural studies of glycoprotein glycosylation to 
support biopharmaceutical realization and the discovery of 
glycan biomarkers for human disease. For biopharmaceu-
ticals, there is increasing use of glycomics in Quality by 
Design studies to help optimize glycan profiles of drugs 
with a view to improving their clinical performance. Gly-
comics is also used in comparability studies to ensure con-
sistency of glycosylation both throughout product devel-
opment and between biosimilars and innovator drugs. In 
clinical studies there is as well an expanding interest in the 
use of glycomics—for example in Genome Wide Associa-
tion Studies—to follow changes in glycosylation patterns 
of biological tissues and fluids with the progress of certain 
diseases. These include cancers, neurodegenerative disor-
ders and inflammatory conditions. Despite rising activity 
in this field, there are significant challenges in performing 
large scale glycomics studies. The requirement is accu-
rate identification and quantitation of individual glycan 
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modification where glycans are attached to proteins dur-
ing translation, assisting in the folding and quality control 
of the protein. Attached glycans are subsequently modified 
in the endoplasmic reticulum and Golgi to varying levels 
of complexity, causing glycosylation to be one of the most 
complex and diverse types of protein modification.
Glycomics is of interest to biopharma companies because 
glycans can greatly modify safety and efficacy profiles of 
the therapeutic protein to which they are attached. For 
example, IgG effector functions such as antibody-dependent 
cellular cytotoxicity and complement-dependent cytotox-
icity of monoclonal antibodies are modulated by N-gly-
cosylation of its fragment crystallizable (Fc) portion [3]. 
N-glycosylation modifications are also involved in deter-
mining the plasma half-life of glycoproteins by modulat-
ing the interaction with various receptors [4, 5]. Even small 
changes in glycosylation can lead to serious issues such 
as anaphylaxis in patients and the destruction of therapeu-
tic activity. These effects have been found in drugs such as 
Cetuximab (a monoclonal antibody (mAb) for treatment of 
metastatic colorectal cancer), Herceptin (a mAb for treat-
ment of breast cancer) and erythropoietin (EPO—a drug for 
increasing red blood cells in patients with renal failure and 
cancer patients undergoing chemotherapy). Given this, there 
are now increasing pressures from regulatory authorities 
for drug manufacturers to measure, optimize and control 
their drug’s glycosylation [6]. This task is very challeng-
ing given the structural complexity of biopharmaceutical 
glycosylation and achieving it has required adoption of a 
new approach to drug design—namely Quality by Design 
(QbD). This methodology has been actively promoted by 
the FDA and other drug regulators and is being adopted by 
leading biopharma companies as the system of best practice 
for the design, development, and manufacture of biologic 
drugs. QbD has the potential to deal with the complexities 
of drug glycans and could help simplify difficult tasks such 
as demonstrating comparability of biopharmaceutical gly-
cosylation [7]. However, the glycoprofiling effort required 
for QbD is considerable. Studies of the QbD approach by 
the CMC Biotech Working Group (a consortium of experts 
from leading biopharma organizations including Genen-
tech, Amgen, Eli Lilly, and Pfizer), indicate that definition 
of the QbD Design Space may require analysis of tens of 
thousands of drug samples [8]. Successful adoption of QbD 
for development of glycoprotein therapeutics requires gly-
coprofiling systems that can cope with this very high level 
of sample throughput—in effect it will need to be built on a 
glycomics framework [6].
In addition to its use in biopharmaceutical realization, 
there is also increasing interest in glycomics for devel-
opment of new clinical diagnostics based on glycosyla-
tion markers of diseases. This follows from the key roles 
that glycans play in major biological processes from 
the fertilization of eggs by sperm to cell death and their 
involvement in a multitude of disease etiologies and pro-
gressions. The potential of glycans as sensitive disease bio-
markers is particularly high, since they are synthesized by 
the concerted action of multiple proteins, and influenced 
by various disease-associated factors such as genetic varia-
tions, epigenetic signatures and metabolic distortions. Gly-
can patterns of secreted proteins often confer information 
on the pathophysiological status of the secreting cells, mak-
ing glycosylation analysis of relevant glycoproteins a suita-
ble diagnostic tool. Changes in glycosylation are associated 
with various diseases like cancer, neurodegenerative and 
inflammatory diseases [9–15]. These types of associated 
changes have resulted in an increased interest in studying 
the alterations in glycosylation patterns of biological fluids 
as disease biomarkers as well as for patient stratification 
and personalized medicine [16].
To date, two glycan biomarkers have been introduced 
for routine clinical diagnostics, namely carbohydrate-defi-
cient transferrin for the detection of alcohol abuse [17] and 
fucosylated serum alpha-fetoprotein for the early diagnosis 
of hepatocellular carcinoma [18]. Importantly, glycomic 
changes are not limited to single conditions but are rather a 
hallmark of virtually any human disease, as stated recently 
in a whitepaper by Walt et al. [16] and diverse promising 
glycomic biomarkers have been described for MODY-type 
diabetes and immunoglobulin G myeloma [19, 20]. How-
ever, most of the glycan biomarkers discovered so far have 
been studied using glycoanalytical technologies that would 
not be suitable for use in routine clinical diagnostic labs—
the shortfall being due mainly to limitations in sample 
throughput, resolution and affordability of the methods.
Given the above, it is clear that development of reliable, 
affordable, high-resolution HTP glycomics technologies 
would be essential in the biopharma industry for efficient 
optimization of the glycosylation patterns of glycoprotein 
therapeutics as well as advancement of practical clinical 
diagnostics based on glycosylation biomarkers of disease.
The rest of this review will cover a number of recent 
advances in glycomics technologies for these two appli-
cations. It highlights current challenges in analytical gly-
comics methods and presents some approaches of how 
the bottlenecks in protein glycosylation analysis may be 
overcome.
High‑Throughput Sample Preparation
Many reviews describe glycan sample preparation steps 
such as N- and O-glycan release, de-glycosylated sample 
desalting and clean-up, derivatization of released glycans 
and analysis using different analytical platforms [21–25]. 
Here we describe a number of recent sample preparation 
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methods for HTP glycosylation analysis. Next to their 
application in biomedical research, these methods are often 
applied for the characterization of biopharmaceuticals.
Liquid chromatography (LC) is a widely used glyco-
analytical technique with good quantification, reproduc-
ibility, and separation of glycan isomers. Royle et al. [26] 
have demonstrated a HTP sample preparation for high 
performance LC (HPLC) using a polyvinylidene fluoride 
(PVDF) membrane and an in-gel block method for glycan 
release. The enzymatic release step is followed by 2-amin-
obenzamide (2-AB) labeling and purification using micro-
plates, and subsequent HPLC analysis. Automation of the 
procedure was achieved to a large extent, as well as the 
automated analysis of the obtained results, but the result-
ing method is still labor intensive, particularly the in-gel 
block preparation and glycan release stage. Performing the 
whole process on 96 samples takes 3 days with an addi-
tional 2 days for the acquisition of the chromatographic 
data. Cook et al. [27] used the rapid deglycosylation kit and 
instant 2-AB kit from Prozyme to demonstrate an approach 
that only took 3.5 h of sample preparation time. A downside 
here is that the required kits are a considerable cost factor, 
which may limit the number of samples that can be studied. 
Burnina et al. [28], on the other hand, have described a cost 
effective HTP sample preparation method for the charac-
terization of therapeutic antibody N-glycosylation taking 
approximately 90 min. The workflow included the follow-
ing steps, denaturation, reduction, deglycosylation using a 
hydrophobic Immobilon-P PVDF membrane filter plate, 
fluorescent labeling and clean-up using a 96-well hydro-
philic filter plate. They demonstrated the use of orthogonal 
assays and obtained LC and MS which were in agreement.
Callewaert et al. [29–31] reported capillary gel electro-
phoresis with laser-induced fluorescence detection (CGE-
LIF) using a DNA sequencer for the analysis and profil-
ing of total serum N-glycans labeled with the negatively 
charged, fluorescent label 8-aminopyrene-1,3,6-trisulfonic 
acid (APTS). Ruhaak et al. [32] have demonstrated the 
HTP application of this by optimizing sample preparation 
and employing a system with multiplexed capillaries. After 
protein denaturation and N-glycan release, the glycans 
were labeled with APTS in a 96 well plate and subjected 
to hydrophilic interaction chromatography (HILIC) puri-
fication. Using the multiplexed CGE-LIF system, 48 sam-
ples can be analyzed in parallel (scalable to 96 samples) 
allowing the analysis of 96 samples with a hands-on time 
of 2.5 h. A recent large-scale application making use of 
the multiplexed CGE-LIF system is the analysis of alpha1-
antitrypsin and immunoglobulin A from over 2,400 human 
plasma samples [33]. Set up to discover novel biomarkers, 
the method revealed protein glycosylation to be associated 
with age and sex, as well as with cardiovascular and meta-
bolic diseases.
Varadi et al. [34] described the use of magnetic beads 
for rapid, HTP sample preparation of N-glycans from thera-
peutic antibodies and indicate that this method is easily 
automatable. The carboxyl coated magnetic beads are capa-
ble of capturing released N-glycans due to the ionic interac-
tion between the positively charged glycosylamines and the 
negatively charged carboxylated beads. The glycans were 
captured using the magnetic beads and were labeled with 
APTS for 2 h. Once again the magnetic beads were used 
for binding the labeled glycans and elution was accom-
plished by washing the beads with water. This eluent was 
suitable for direct analysis by CE-LIF.
Mass spectrometric analysis of glycans is difficult when 
dealing with isobaric structures and particularly diffi-
cult when dealing with sialylated species. Sialic acids are 
known to degrade under harsh sample preparation and ioni-
zation conditions, as well as showing a strong preference 
towards negative ionization. Sialylated glycans are often 
derivatized before mass spectrometric analysis, either by 
carboxylic acid-specific methods or permethylation [35].
Gil et al. [36] reported a one pot sialic acid amidation 
reaction using acetohydrazide, allowing neutralization of 
sialylated N-glycans still attached to proteins. Accidental 
Schiff base formation with the acetohydrazide is prevented 
because the glycans are still attached to the protein. N-gly-
can release could then be performed afterwards, as well 
as labeling with the negatively charged fluorescent label 
2-aminobenzoic acid (2-AA). Clean-up was performed by 
96-well filter plate, and analysis by MALDI-time of flight 
(TOF)-MS. The authors used recombinant human glyco-
proteins to determine changes in fucosylation and changes 
in sialylation and compared the MALDI–TOF–MS data 
with HILIC HPLC data proving that they were in good 
agreement. Another approach used by Jeong et al. [37] for 
HTP quantitative N-glycan analysis was solid phase per-
methylation. Sialylated N-glycans were protected with a 
methyl group at the carboxylic acid by the permethylation 
reaction, and glycan mixtures were subsequently analyzed 
by MALDI–TOF–MS in positive ion mode. Sample prepa-
ration steps were performed in a 96-well format, compris-
ing glycoprotein binding on PVDF, deglycosylation, puri-
fication of N-glycans by porous graphitized carbon (PGC), 
and solid phase permethylation. By spiking a known con-
centration of internal standard mixture with ovalbumin and 
porcine thyroglobulin, the authors obtained absolute quan-
titation for these samples, as well as relative quantification 
of 49 glycans from human serum prostate specific antigen. 
The complete sample preparation utilizing this method 
takes 2 days, but is quite labor intensive due to multiple 
manual pipetting steps.
Miura et al. [38] have developed a protocol for the 
methyl esterification of sialic acids using 3-methyl-1-p-
tolyltriazene (MTT) as sole reactant and methyl group 
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donor. This derivatization was performed on both the free 
N-glycans, requiring a subsequent purification step, as 
well as after immobilization of the N-glycans on Affi-gel 
beads, allowing a much increased throughput. Glycans 
could be analyzed afterwards by MALDI–TOF–MS with 
significantly increased stability. Using this method, both 
the neutral glycans and the previously negatively charged 
sialylated glycans could be observed in the same posi-
tive mode spectrum. Liu et al. [39], have shown a similar 
increase in sialic acid stability after methylamidation of 
the carboxylic acid residues with a combination of meth-
ylamine and tripyrrolidinophosphonium hexafluorophos-
phate (PyAOP). They have shown this approach to be suit-
able for the derivatization of O-acetylated sialic acids, and 
were able to perform both MALDI and electrospray ioniza-
tion (ESI)-MS (/MS) experiments on the glycans. Both the 
MTT and the PyAOP stabilization methods only require a 
few hours of preparation time (purification included), mak-
ing them suitable for HTP glycomics.
Another variant of methods for sialic acid modification 
can make use of the chemical nature of α2,3-linked sialic 
acids to lactonize with the subterminal galactose resulting 
in a loss of water that can be observed in mass spectrom-
etry, whilst α2,6-linked sialic acids show no such behavior. 
Published by Wheeler et al. [40], the use of 4-(4,6-dimeth-
oxy-1,3,5-triazin-2-yl)-4-methylmorpholinium (DMT–
MM) in combination with methanol showed good reac-
tion selectivity for the sialic acid linkages, generating 
either lactones or methyl esters. Alley et al. [41] have used 
DMT-MM to generate amides instead of esters, perform-
ing the reaction in the presence of ammonium chloride. 
Subsequent permethylation still showed linkage-specific 
mass differences, with the added benefit of more informa-
tive fragmentation spectra. Another extension of the DMT-
MM deriviatization method was shown by Tousi et al. [42] 
who performed nano-HILIC-Orbitrap-MS of the modified 
glycans, effectively increasing the number of individual 
resolvable peaks after HILIC separation, as well as allow-
ing linkage-specific MS(/MS). Similar to MTT and PyAOP, 
DMT-MM-assisted modification can be performed in less 
than 3 h (with the reaction conditions and reaction time 
depending on the modification to be introduced), and is 
highly suitable for HTP sample preparation.
An alternative to the DMT-MM method for linkage-spe-
cific modification has recently been published by us using 
the combination of 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) as 
chemicals for derivatization [43]. Performed in ethanol, the 
reaction yields highly linkage-specific products when incu-
bating at 37 °C for 1 h (lactones for α2,3-linked sialic acids 
and ethyl esters for α2,6-linked sialic acids), with more 
resistance to side reactivity (such as amidation) than with 
DMT-MM. As a result, the method could be performed 
directly on impure glycan-containing mixtures such as 
a peptide-N-glycosidase F (PNGase F)-released plasma 
N-glycome. The protocol has been validated for HTP appli-
cation in 96-well plate format, and shows consistent results 
with ultra-performance liquid chromatography (UPLC)-
based methods of analysis [Fig. 1]. An application has 
recently been published by Bondt et al. [44] who have stud-
ied glycosylation changes on IgG fragment antigen-binding 
(Fab) and Fc, at different time points during and after preg-
nancy. By analyzing a total of 576 glycan profile spectra, 
pregnancy-associated changes were revealed in IgG Fab 
glycan sialylation, galactosylation, bisection, fucosylation, 
and high mannose structures.
Modification and stabilization of glycoconjugates has 
recently been attempted by Nishikaze et al. [45], show-
ing a PyAOP-based methylamidation of all carboxylic 
acids present on sialylated glycopeptides. Not only does 
this derivatization protect the sialylated glycan species 
from breakdown, MALDI-quadrupole ion trap-TOF–MS 
fragmentation shows increased structural information as a 
consequence. Nishikaze and coworkers observed predomi-
nantly peptide fragmentation in positive mode collision-
induced dissociation MS/MS, while negative mode led to 
more information on glycan structural features. Using a 
different glycopeptide derivatization method, Amano et al. 
[46] modified glycopeptides with 1-pyrenyldiazomethane, 
also specifically targeting carboxylic acids. Whilst this 
method leads to enhanced ionization for MALDI–MSn 
analysis, the subsequent exploration of the fragmentation 
has shown fragment ions reflecting predominantly sialic 
acid linkage cleavage [47].
For the HTP analysis of underivatized Fc IgG tryptic 
glycopeptides, Selman et al. [48] have published a method 
employing MALDI-Fourier transform ion cyclotron reso-
nance (FTICR)-MS. The advantage of this intermediate-
pressure instrument is the tendency for labile substituents 
to remain intact without chemical stabilization, allowing 
directly for the analysis of sialylated glycopeptide spe-
cies [49]. Using 96-well sample preparation, Selman et al. 
showed a highly repeatable analysis of 384 samples in less 
than 36 h, comprising all of the steps from capturing of the 
IgG to automatic processing of the spectra. Additionally, 
the same group established a HPLC–MS method for meas-
uring IgG-Fc glycopeptides requiring 16 min analysis time 
per sample, employing a sheath-flow electrospray setup for 
enhanced sensitivity and robustness [44]. Large-scale appli-
cations of this method have been performed by Bondt et al. 
[50], analyzing over 1,500 samples within 4 weeks with an 
internal standard coefficient of variation (CV) below 4 %. 
The results indicated an association between IgG galac-
tosylation and improvement of rheumatoid arthritis (RA) 
during pregnancy. Another application was performed by 
Rombouts et al. [51] who have used the method to show 
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changes in anti-citrullinated protein antibody Fc glycosyla-
tion even preceding the onset of RA. Both the FTICR and 
HPLC methods separate IgG glycopeptides on the basis of 
single amino acid differences (phenylalanine or tyrosine) 
allowing subclass-specific glycosylation analysis. An over-
view of various HTP methods for IgG glycosylation analy-
sis has been published by Huffman et al. [52], comparing 
UPLC with fluorescent detection, MALDI–TOF–MS, mul-
tiplexed CGE-LIF and LC–ESI–MS, as well as explaining 
the advantages and disadvantages of each method.
Another highly sensitive technique for analysis of pro-
tein glycosylation utilizes multiple reaction monitoring 
(MRM) which is an LC–MS/MS technique performed on 
a triple quadrupole (QqQ). MRM is known for its ability 
to quantify low abundant compounds in highly complex 
mixtures. For example, glycoproteins from biological fluids 
like serum or plasma are reduced, alkylated and digested 
with trypsin and analyzed without further fractionation 
[53]. In MRM glycans or glycopeptides are scanned in the 
first quadrupole (Q1) for user specified precursor ions and 
these precursors undergo CID in the second quadrupole 
(Q2) and fragments are produced. Finally the fragments 
of the precursor ions, known as transitions are scanned in 
the third quadrupole [54]. Song et al. [54] used MRM for 
quantifying glycopeptides from both model glycoproteins 
and from depleted human blood serum. Hong et al. [53, 55] 
also reported the use of MRM for absolute quantitation of 
IgG glycopeptides and also published the use of MRM to 
study site specific glycosylation alterations for identify-
ing glycan biomarkers. The advantages of the technique 
are the very high sensitivity which together with the high 
selectivity allows for the direct analysis of the resulting 
glycopeptides on the QqQ without requiring prior protein 
enrichment or sample clean-up. A couple of drawbacks to 
this technique are that (1) MRM analyses are targeted, and 
analytes/glycopeptide species which are not included in the 
method set-up cannot be detected by data mining in hind-
sight. (2) A considerable amount of time and effort need to 
be invested for assay set-up and for establishing transitions 
for different analytes. These above mentioned MRM proto-
cols were not adapted to HTP sample preparation, but can 
certainly be implemented for large sample numbers and 
MRM is envisaged to facilitate glycan biomarker discovery 
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Fig. 1  2-AB-labeled A3 glycan standard from Ludger (CAB-A3-01) 
was analyzed by UPLC and MALDI–TOF–MS after ethyl esteri-
fication. a Overnight incubation at 37 °C of Ludger 2-AB-labeled 
A3 standard with buffer (red), α(2,3)-sialidase (green), α(2,3/6/8)-
sialidase (blue), α(2,3/6/8)-sialidase + β(1,4)-galactosidase (orange). 
Separation was performed on a Waters Acquity UPLC H-class sys-
tem using an Acquity BEH 1.7 µm 2.1 × 150 mm glycan column. 
b Linkage-specific assignment of the undigested UPLC data [100]. 
c MALDI–TOF–MS spectrum of the 2-AB-labeled A3 standard 
([M + Na]+) after 1 h of ethyl esterification with EDC and HOBt at 
37 °C and subsequent HILIC purification according to Reiding et al. 
[43]. Profiles obtained from both methods are highly comparable and 
show similar ratios with regard to sialic acid occupancy and linkage. 
HILIC peak assignments are based on the exoglycosidase digests, as 
well as use of internal standards. Structural schemes of glycans are 
depicted following the CFG notation: N-acetylglucosamine (blue 
square), fucose (red triangle), mannose (green circle), galactose 
(yellow circle), N-acetylneuraminic acid (purple diamond). Known 
N-acetylneuraminic acid linkages are indicated by a left angle (α2,3) 
or right angle (α2,6), and otherwise unspecified
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Use of Internal Standards
The analysis of glycosylation is made difficult by techni-
cal variation with respect to separation (retention time, 
m/z values) and intensity (fluorescent signal, ion detec-
tion). In particular, the analysis of complex samples is 
compromised by the presence of the biological matrix 
that can influence labeling as well as ionization effi-
cacy and migration positions [56, 57]. The use of stand-
ards has been found to assist tremendously in identifica-
tion and quantification of glycans, and many interesting 
approaches have been shown in the literature to internal-
ize standardization within HTP sample analysis. When 
using a DNA analyzer for CGE-LIF analysis of labeled 
glycans, the fact can be exploited that the system can 
analyze fluorescence on different wavelength channels. 
Using multiplexed CGE-LIF, co-injection of fluorescently 
labeled glycans and a base-pair nucleotide ladder fluo-
rescing at a different wavelength was performed allowing 
for the correction of glycan migration times on the basis 
of the nucleotide ladder [32].
Glycan standards labeled with heavy isotopes facilitate 
quantitation during mass spectrometric analysis of deri-
vatized glycans. For example, Prien et al. [58] have quan-
titatively analyzed the N-glycosylation of several standard 
proteins by MALDI–TOF- and nanospray multistage-MS 
after labeling with normal 2-AA and a heavy 13C version 
of 2-AA. The molecular weight difference between the two 
labels gives an offset of +6 Da. Mixing various ratios of 
the differently labeled samples revealed consistent quan-
titation by mass spectrometry. Using a different labeling 
chemistry, Walker et al. [59] developed stable-isotope 
labeled hydrazide reagents for ESI–MS(/MS) analysis and 
showed quantitative detection after a sample preparation 
procedure that takes approximately 4 h. As another exam-
ple, Zhang et al. [60] have presented stable isotopically 
labeled phenyl-3-methyl-5-pyrazolone at the N-glycan 
reducing end with quantitation achievable within a 10-fold 
dynamic range.
Another labeling strategy for quantification lies in the 
use of isobaric tags. Variants of these labels have the same 
mass, but differ in the distribution of heavy isotopes on 
opposite sides of a bond that readily undergoes fragmen-
tation by CID. Reporter ions in MSn experiments can be 
used for relative quantification, making quantitation of 
highly complex samples intrinsically more robust than in 
MS mode quantitation, as the latter method can easily suf-
fer from interfering, overlapping signals. An example of the 
use of isobaric tags in glycosylation analysis is provided 
by Ahn et al. [61] who show LC–MS/MS data on tryptic 
glycopeptides derivatized with isobaric tags for relative 
and absolute quantitation (iTRAQ) at the peptide primary 
amines. Another version of isobaric tags are tandem mass 
tags (TMT), which have been used by Gong et al. [62] to 
label released N-glycans still in their glycosylamine form. 
Glycosylamines are generated when PNGase F release 
is performed, but usually hydrolyze to the reducing sugar 
under most conditions. However, keeping the pH slightly 
alkaline preserved the glycosylamines and allowed for 
TMT labeling by N-hydroxysuccinimide ester chemistry 
[62]. Both iTRAQ and TMT not only facilitate internal 
standardization, but also allow the discrimination of multi-
ple different samples during a single analysis, speeding up 
analysis time as a consequence.
Permethylation provides another opportunity to gener-
ate internal standards. For example, when a 13C permethyl-
ated glycan standard of known concentration is mixed with 
a 12C permethylated glycan sample and analyzed by MS, 
relative glycan quantitation data can be obtained. Manilla 
et al. [63] have published the use of 13C methyl iodide for 
permethylation, showing expected ratios at various concen-
trations when comparing to 12C permethylated human milk 
oligosaccharides using MALDI–TOF–MS. 12C and 13C 
permethylated human IgG N-glycan standards developed at 
Ludger are an example of system suitability standards used 
for relative quantitation [Fig. 2]. When in possession of 
mass spectrometric instruments with high resolving power, 
Atwood et al. have shown isobaric variants can also be used 
for permethylation. Using 13CH3I and 12CH2DI as methyl 
donors, a minimal mass difference (0.0029 Da) is imparted 
upon the glycan permethylation site. When analyzed with 
high resolution instruments such as FTICR-MS the variants 
can be separated, achieving relative quantitation over two 
orders of magnitude, while a single peak can be generated 
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Fig. 2  MALDI–TOF–MS spectrum of the 12C and 13C permethylated 
human-IgG N-glycan standards from Ludger (Cat# Cpm13C-IgG-01 
and Cpm12C-IgG-01). 13C was spiked with 12C on the same sample 
spot to showcase the comparison of relative quantities of the major 
IgG N-glycans. The mass values shown in the spectra are [M + Na]+ 




Integration of Analysis Workflows
Various groups have attempted to integrate different parts 
of the work-up procedure and simplified sample prepara-
tion steps. The integration of workflows has the potential 
to expedite analyses of a wide range of glycans, and the 
approaches can provide significant advantages in produc-
tivity, sensitivity, speed, and efficiency. Methods focusing 
on the integration of workflows are discussed below.
BlotGlyco kits produced by Sumitomo Bakelite in Japan 
integrate and support an “all-in-one” solution for auto-
mated and HTP analysis [65]. Glycoproteins are cleaved 
with trypsin, glycans are released by PNGase F, captured 
chemoselectively on hydrazide-functionalized beads cou-
pled to 2-AB, and modified at the sialic acids by MTT as 
described previously. Subsequently, the N-glycans are 
released from the beads by reduction of sulfide bonds, but 
by that process retain 2-AB as a label. Using this integra-
tion method up to 96 samples can be purified and labeled 
in about 8 h. A newer method of Sumitomo Bakelite uses 
hydrazide beads to capture glycans in a process called gly-
coblotting, the captured glycans are purified, released from 
the beads and then labelled with 2AB on a 96 well filter 
plate [66].
Another integrated system is the Agilent mAb-glyco 
chip kit which has been designed for automated charac-
terization of N-glycans from monoclonal antibodies (mAb) 
[67]. The system integrates on-chip deglycosylation of the 
mAb, HPLC chromatographic separation, quadrupole time-
of-flight (QTOF)-MS analysis of the released glycans, as 
well as data analysis by Molecular Feature Extractor which 
is a part of Agilent’s data analysis software MassHunter. A 
study comparing on-chip and in-solution deglycosylation 
methods showed that the analysis time could be reduced 
from 5 to 6 h to 12 min [68]. Another microchip-based 
integrated platform is the Caliper LabChip GXII Micro-
chip-CE Platform, which uses the Caliper ProfilerPro gly-
can profiling kit to provide a HTP method for analyzing 
N-glycosylation patterns on mAbs and other glycosylated 
proteins [69]. The system contains plates for denaturation, 
deglycosylation, and glycan labeling. The analysis is per-
formed on a LabChip GXII CE instrument together with an 
internal standard. By this method, the relative abundance of 
the major N-glycans found on mAbs can be determined in 
a short span of time, requiring only 90 min for the prepara-
tion of 96 samples, although the glycan peak separation is 
compromised.
Automation of Sample Preparation
While the development of HTP methods for analysis of 
glycosylation facilitates the glycomic study of large clinical 
cohorts, performing manual sample preparation is still a 
time-consuming process. Additionally, while performing 
manual work-up is suitable for small sample sets, scaling 
up to larger sizes may lead to errors and inconsistency, 
resulting in poor repeatability. This set of circumstances 
has led to an increasing demand for automation of work-
flows, with laboratories requiring a system that is simple 
to operate, has scalable sample preparation and a process 
that is both repeatable and reliable. Currently, high qual-
ity glycomics data can be obtained using liquid handling 
robots for sample processing, clean-up and sample prepara-
tion [70]. A few approaches for automated and HTP glycan 
analysis will be reviewed.
Stöckmann et al. published an automated workflow for 
IgG N-glycan release, hydrazide bead capture of glycans 
through glycoblotting adapted from the protocol of Furu-
kawa et al. mentioned above, 2-AB labeling, solid phase 
extraction (SPE), LC separation, and quantification. This 
workflow was developed for the efficient glycoprofiling of 
bio-therapeutics and clinical samples on the Hamilton Star 
liquid handling robot [14]. This approach was tested for the 
analysis of protein A captured IgG derived from CHO cells, 
as well as for the analysis of 100 samples of protein G-cap-
tured human IgG. The automated glycan preparation was 
verified with conventional and manual in-gel block release 
for the human serum IgG N-glycans, with CVs below 10 % 
for all major glycan peaks, and with relative ratios in agree-
ment with expectation.
A second integrated and automated technology devel-
oped specifically for biomolecule sample preparation is the 
Agilent AssayMAP platform, which is supported by the 
Bravo automated liquid-handling robot [71]. This work-
flow utilizes ProZyme GlykoPrep-plus chemistry kits, with 
an optional affinity purification step to capture glycopro-
teins from cell lysates, cell culture supernatants, or serum. 
Recoveries in glycoprotein purification approach 100 % for 
most applications, with CVs of ≤5 %. The purified glyco-
proteins are denatured and immobilized onto hydrophobic 
cartridges. Next, the immobilized glycoprotein samples are 
treated with PNGase F, the glycans fluorescently labeled, 
and cleaned on HILIC cartridges prior to analysis by 
HPLC, CE, or LC–MS [72]. The automation platform ena-
bles processing of complex samples, increases throughput, 
decreases variability and decreases assay time from a cou-
ple of days to 3–5 h. However, the cost of the kit could be a 
limiting factor when analyzing a large number of samples.
Another automated analytical workflow supported 
by the Hamilton STARlet liquid handling robot has been 
developed at Ludger for HTP glycomics for QbD studies. 
The automated workflow combines glycan release, 2-AB 
labeling, clean-up, and sample preparation for UPLC anal-
ysis. A validation study was performed, starting with 16 
human IgG samples that were released by using PNGase 
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F. Each sample was divided into four and the four subsets 
of samples were further divided equally into two 96 well 
PCR plates. Two operators used the liquid handling robot 
to label one plate each with 2-AB and cleaned-up using the 
liquid handling robot. The CVs for the major human IgG 
N-glycan peaks between the different operators were below 
5 % [73]. In addition, a fully robotized analysis for 48 sam-
ples of human IgG was performed, starting from the N-gly-
can release up to UHPLC sample preparation, showed CVs 
less than 5 % for all peaks with average areas above 1 % 
[Fig. 3].
For mass spectrometric analysis of glycopeptides, 
Reusch et al. [74] have developed a fully automated HTP 
sample preparation method employing the Hamilton Micro-
lab STAR to monitor mAb IgG Fc glycosylation by Orbit-
rap ESI–MS. They studied IgG from fermentation superna-
tant, automating the protein A capturing, tryptic digest, and 
HILIC-SPE, showing that the automation produces highly 
similar results when compared to HILIC-HPLC analysis 
of 2-AB labeled glycans, MALDI–TOF–MS and high-pH 
anion-exchange chromatography-pulsed amperometric 
detection of released glycans, as well as ESI-QTOF–MS of 
reduced mAb Fc. The glycopeptide sample preparation per-
formed in this protocol facilitates discrimination between 
Fc and Fab portions, allows subclass-specific analysis, and 
is usable for a wide range of readout methods.
Data Analysis
Innovations in sample preparation have increased the scope 
of glycomics considerably, allowing recently, for example, 
for large-scale GWAS [19, 75]. However, increased data 
production leads to an accompanying need for robust and 
HTP data analysis procedures. The techniques focused on 
in this review allow the detection of large numbers of sam-
ples either by being HTP, or by featuring automation lead-
ing to decreased hands-on time. Such methods can be used 
for the discovery of analytes (glycans), but are most help-
ful for the repeated detection of similar glycosylation fea-
tures across large cohorts. As a consequence, there is need 
for software capable of repeated and robust HTP feature 
8 10 12 14 16 18 min
b
a
Fig. 3  a Workflow depicting validation study of semi-automated 
sample preparation of 48 replicates of human IgG samples, compris-
ing digestion by PNGase F, 2-AB-labeling, HILIC SPE enrichment 
and preparation of samples for injection onto UHPLC performed 
with Hamilton Starlet liquid handling robot [73, 101, 102]. b Typical 
UHPLC chromatogram of 2-AB-labeled human IgG glycans prepared 
using the robot. Analysis of the data from these 48 samples showed 
CVs less than 5 % for all major peaks. The data shows that the auto-
mated, high-throughput method is repeatable. The liquid handling 
robot allows for fast, reliable and robust analyses of glycans. Glycan 
peaks in the chromatogram were assigned by exoglycosidase diges-
tion, standard inclusion, and literature [103]
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extraction and quality control. Most analysis platforms and 
integrated methods have their software solutions, several 
having been mentioned above, but usually these are closed 
source, require licensing and may not cater to the function-
ality required by a user.
We recently reported an automated data extraction 
method for MALDI–TOF–MS spectra of N-glycans after 
sialic acid ethyl esterification [76]. This script requires 
Python, a programming language to be installed (freely 
available from www.python.org), which is capable of 
repeatedly integrating a list of glycan compositions from 
any number of mass spectra. The script calculates the 
expected glycan masses, allows a variety of modifications, 
takes the resulting isotopic distributions into account, and 
performs local background subtraction. As a downside, the 
program needs already calibrated data, and requires the 
user to still manually perform quality control.
Next to software for repeated analysis of data, several 
groups have published tools for the interpretation and assign-
ment of glycomic and glycoproteomic data. These tools have 
been comprehensively reviewed by Woodin et al. [77] and 
Dallas et al. [78]. Notable and freely available examples of 
de novo interpretation of mass spectrometric data include 
Glyco-Peakfinder [79], GlycoSpectrumScan [80], GlycoPep 
Grader [77], SysBioWare [81], GlycoMiner [82], and GlypID 
[83]. Interpretation by matching recorded data to a previously 
annotated database can be performed for mass spectrometric 
data by GlycoPeptide Search [84], GlycoSearchMS [85], and 
GlycoPep DB [86], while HPLC derived glycan traits can be 
interpreted by GlycoExtractor [87] and autoGU [88].
Glycomic and glycoproteomic databases have been 
reviewed by Hizal et al. [89] and Campbell et al. [90], of 
note being the metadatabases GlycomeDB (containing 
entries from CFG, KEGG, GLYCOSCIENCES.de, BCSDB 
and Carbbank) [91], and UniCarbKB (containing entries 
from GlycosuiteDB, EUROCarbDB, UniCarb-DB and Gly-
coBase) [92]. GlycomeDB and UniCarbKB contain a wealth 
of theoretical and experimentally observed glycan structures, 
site-specific information on protein glycosylation, alongside 
various tools for retrieving and displaying the information.
Helpful with the graphical annotation of spectra are 
the web-based GlycanBuilder and DrawRings, allowing 
the facile construction of CFG or Oxford type glycan car-
toons [93, 94]. Particularly useful for glycan analysis is the 
desktop application GlycoWorkBench [95]. The program 
combines many aspects of glycan annotation and glycan 
spectral interpretation into a user-friendly package, incor-
porating GlycanBuilder for cartoon annotation, GlycoPeak-
finder for theoretical structure prediction and interpretation, 
as well as several others for the automatic assignment of 
spectra, database searching, and many other functions.
All tools mentioned here are freely accessible web-based 
applets, or can be obtained without requiring payment.
Conclusion
Analysis of glycosylation is often a major challenge due to 
the vast macro-heterogeneity of glycoproteins, i.e., a sin-
gle protein can have a varying number of occupied N- and 
O-glycosylation sites. Additionally, a single site can be 
occupied by a variety of glycans, which is known as micro-
heterogeneity [2]. Furthermore, the analysis of glycans is 
complicated by variations in linkage and branching patterns 
which may lead to multiple isomers.
LC has long been the gold standard for analysis of fluo-
rescently labeled glycans, providing good sensitivity, iso-
mer separation, accurate glycan quantitation, repeatability, 
and in-depth characterization when supported by exogly-
cosidase sequencing. Downsides, however, are low sample 
throughput and relatively high cost per sample when com-
paring to, for example, MS-based methods of analysis [52]. 
MS on the other hand, provides good sensitivity, structural 
elucidation options via MSn experiments, good sensitivity, 
as well as very high throughput in case of MALDI ioni-
zation. Downsides here are the limitations in isomer sep-
aration and quantitation, and instability of labile groups 
when no derivatization is performed [96]. CGE-LIF sup-
ports high sensitivity, high throughput when multiplexed, 
and low running costs especially when comparing to LC. 
Unfortunately, databases for CGE-LIF annotation are small 
and could be a limiting factor.
Hyphenation of glycomic LC and CE methods with 
online MS detection, optionally in combination with fluo-
rescence detection of labeled glycans, may add confidence 
in glycan structural assignment as both migration posi-
tion and (tandem) mass spectrometric information can be 
combined [97, 98]. However, it should be noted that cer-
tainly CE separation of glycans is often compromised by 
the restrictions faced with MS coupling. Further limitations 
in LC and CE hyphenation for glycomics are the relatively 
high costs due to medium sample throughput.
As demonstrated in this review, many of the analysis 
methods are moving towards increasingly HTP sample 
preparation, making use of multiwell formats, employing 
derivatizations with brief and manageable reaction times, 
integration of time-consuming steps and providing solu-
tions for rapid analysis of the acquired data. Addition-
ally, this progress towards simpler protocols provides the 
opportunity for liquid handling robots like the Hamilton 
and Bravo types to take over many of the time-consuming 
and labor- as well as cost-intensive steps. These automated 
platforms often show similar performance to expert manual 
labor, while even outperforming manual preparation when 
large cohorts are measured.
A common motif for HTP methodology is the inclusion 
of a solid support glycan binding or adsorption step. This 
can be used for purification, often in the form of covalent 
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binding. When using chemical methods for capturing such 
as beads containing reactive hydrazide groups, this pro-
vides the opportunity for efficient labeling. This kind of 
integration is an excellent example of development towards 
shorter and easier protocols. Labeling itself is moving 
towards the use of heavy isotopes, to allow for reliable 
quantitation with mass spectrometry. The derivatization 
steps required for proper analysis of sialylated glycan spe-
cies, notably permethylation and sialic acid-specific strate-
gies, and several methods have been successful to date [99].
While mass spectrometry is one of the most HTP tech-
niques possible for the analysis of glycans and glycoconju-
gates, it is hampered by its inability to provide quantitative 
data. This makes the various efforts undertaken for inter-
nal standardization, and thereby allowing quantitation, an 
exciting field to watch. The two main strategies for inter-
nal standardization are the use of heavy isotopic variants 
of glycans as well as the use of isobaric tags with unequal 
mass distribution. In both cases, the most convenient way 
to introduce mass differences is by employing derivatiza-
tion steps already part of an analysis protocol, such as labe-
ling or stabilization. A second strategy would be the spik-
ing of a sample with a known concentration of a standard 
modified with a heavy isotope, which would also allow for 
the use of heavy isotopic variants of underivatized glycans. 
Convenient mass differences for internal standards are a 
few milliDalton showing parallel isotopic distributions on 
high resolution instruments, and onward from a few Dalton 
to prevent the overlapping of the natural istotopic distribu-
tion of glycans and glycopeptides.
With increasingly large studies being performed, the 
bottleneck of glycomics is shifting towards the data anal-
ysis. Current software for automation of analysis mainly 
focuses on interpretation rather than repeatable analysis 
of already interpreted and annotated spectra. There is a 
clear need for software allowing proper feature extraction, 
denoising, background subtraction, and most importantly 
of all, quality control both on individual glycans and com-
plete spectra. Automated interpretation is mostly performed 
assisted by a predefined set of possibilities, or by matching 
experimental data to a database. While several programs 
exist to perform true unassisted de novo annotation, this 
approach has only shown successful on data that is of high 
quality. Particularly for hyphenated analysis methods such 
as LC–MS, manual annotation is still the way to go, and is 
a highly time consuming process.
Altogether, the methodological improvements discussed 
in this article show a clear trend towards more sensi-
tive approaches, with faster analysis, lower costs and less 
hands-on time. These improvements allow for the increas-
ing translation of glycomic approaches to clinical research, 
with envisioned applications in patient stratification and 
personalized medicine.
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